Antipruritic patch

• US 6,469,227 B1
• Filed: 05/12/2000
• Issued: 10/22/2002
• Est. Priority Date: 12/10/1999
• Status: Expired due to Fees

• Current Assignee: LecTec Corporation
• Original Assignee: LecTec Corporation
• Inventors: Cooke, Dede, Rolf, David
• Primary Examiner(s): Lewis, Kim M.
• Application Number:
  US09/569,783
• Time in Patent Office: 893 Days
• Field of Search: 602/41-59, 604/304, 604/305, 604/306, 604/307, 442/441-448, 128/888, 128/889, 128/893, 128/894
• US Class Current: 602/48
• CPC Class Codes: A61K 9/70 Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug hollow drug-filled fibres A61K9/0092
• CPC Class Codes: A61K 9/7061 Polyacrylates
• CPC Class Codes: A61P 17/04 Antipruritics

Abstract

The present invention provides a non-occlusive adhesive skin patch. The patch includes a woven or nonwoven porous backing having a front side and a back side. The patch also includes a therapeutic formulation located on the front side of the backing. The backing includes a flexible sheet of water insoluble porous material. The therapeutic formulation includes a medicament useful for relieving topical discomfort and a pressure sensitive adhesive. The therapeutic formulation optionally includes a solvent that can effectively dissolve the medicament. The present invention also provides a method for alleviating topical discomfort. The method includes applying an adhesive skin patch of the present invention to skin inflicted with a topical disorder.

Claims

1. An adhesive patch comprising a backing of a flexible sheet of water insoluble porous material, the backing having a front side and a back side and a therapeutic formulation positioned on at least a portion of the front side;

wherein the therapeutic formulation comprises;

camphor present up to about 3.0 wt. % of the therapeutic formulation;

menthol present up to about 1.0 wt. % of the therapeutic formulation; and

a pressure sensitive adhesive.

2. The patch of claim 1 wherein the therapeutic formulation is positioned on the entire front side of the backing.

3. The patch of claim 1 wherein the backing comprises a nonwoven fabric.

4. The patch of claim 1 wherein the backing comprises polycellulose fibers, polyester fibers, polyurethane fibers, polyolefin fibers, polyamide fibers, cotton fibers, or any mixture thereof.

5. The patch of claim 1 wherein the backing comprises open cell foam.

6. The patch of claim 5 wherein the open cell foam comprises polyurethane, polyvinyl chloride, polyethylene, or any combination thereof.

7. The patch of claim 1 wherein upon contact with skin, the backing retains the therapeutic formulation and the patch allows moisture from the skin to pass.

8. The patch of claim 1 further comprising a solvent.

9. The patch of claim 1 wherein the solvent is a polyhydric alcohol.

10. The patch of claim 8 wherein the propylene glycol is present up to about 40.0 wt. % of the therapeutic formulation and wherein polyethylene glycol is present up to about 25.0 wt. % of the therapeutic formulation.

11. The patch of claim 1 wherein the pressure sensitive adhesive comprises an adhesive, a polymer, and a humectant.

12. The patch of claim 11 wherein the adhesive comprises a water/lipid emulsion, a hot melt pressure sensitive adhesive, a solvent based pressure sensitive adhesive, a silicone based pressure sensitive adhesive, a resin emulsion adhesive, a water based adhesive, or any combination thereof.

13. The patch of claim 11 wherein the adhesive comprises a water/lipid emulsion, polyacrylate, polyisobutylene, polybutene, rubber, polystyrene-polybutadiene-polystyrene, polystyrene-polyisoprene-polystyrene, polystyrene-poly(ethylene-butylene)-polystyrene block polymers, vinyl acetate resin, acrylic ester copolymer, vinyl acetate/diocyl maleate copolymer, acrylic copolymer, or any combination thereof.

14. The patch of claim 11 the adhesive is an acrylic ester copolymer.

15. The patch of claim 14 wherein the acrylic ester copolymer is present in about 10.0 wt. % to about 25.0 wt. % of the therapeutic formulation.

16. The patch of claim 11 wherein the polymer is vinyl acetate copolymer, polyvinyl pyrrolidone, algin, derivatives of algin, polymaleic anhydride, copolymers of polymaleic anhydride, karaya, xanthan gum, guar gum, polyacrylamide, polyvinyl alcohol, poly AMPS, or polyacrylates.

17. The patch of claim 16, wherein the karaya is present in about 10.0 wt. % to about 50.0 wt. % of the therapeutic formulation.

18. The patch of claim 11 wherein the humectant is glycerin.

19. The patch of claim 18 wherein the glycerin is present in about 10.0 wt. % to about 60.0 wt. % of the therapeutic formulation.

20. The patch of claim 1 wherein the pressure sensitive adhesive is positioned on the entire front side of the backing.

21. The patch of claim 1 wherein the therapeutic formulation further comprises a fragrance.

22. The patch of claim 21 wherein the fragrance is a floral scent, a fruit scent, a plant leaf scent, or any combination thereof.

23. The patch of claim 22 wherein the fragrance is Fresh &

Clean scent.

24. The patch of claim 1 wherein the therapeutic formulation further comprises calamine, aloe, lanolin, glycerin, Vitamin E, Vitamin C, Vitamin E acetate, or any combination thereof.

25. The patch of claim 1 that is individually wrapped or wherein multiple patches are located on a card and the card is individually wrapped.

26. The patch of claim 1 that prevents or diminishes the occurrence of a contaminant from the surrounding environment from contacting the surface of skin inflicted with a topical disorder.

27. The patch of claim 1 that can effectively cover the entire surface of skin inflicted with a topical disorder.

28. An adhesive patch comprising a backing of a flexible sheet of water insoluble porous material, the backing having a front side and a back side and a therapeutic formulation positioned on at least a portion of the front side;

wherein the therapeutic formulation comprises;

camphor present up to about 3.0 wt. % of the therapeutic formulation;

menthol present up to about 1.0 wt. % of the therapeutic formulation; and

a pressure sensitive adhesive;

wherein the adhesive patch can effectively cover the entire surface of skin inflicted with a topical disorder.

29. An adhesive patch comprising a backing of a flexible sheet of water insoluble porous material, the backing having a front side and a back side and an ointment wherein the ointment comprises:

camphor present up to about 3.0 wt. % of the therapeutic formulation;

menthol present up to about 1.0 wt. % of the therapeutic formulation; and

a pressure sensitive adhesive.

30. The adhesive patch of claim 29 wherein the pressure sensitive adhesive is a hot melt adhesive, a solvent based adhesive, a petroleum based adhesive, a water based adhesive, or a combination thereof.

31. A method for alleviating topical discomfort comprising:

applying to the area of the skin inflicted with the topical disorder an adhesive patch comprising a backing of a flexible sheet of water insoluble porous material, the backing having a front side and a back side and a therapeutic formulation positioned on the front side of the backing;

wherein the therapeutic formulation comprises;

camphor present up to about 3.0 wt. % of the therapeutic formulation,

menthol present up to about 1.0 wt. % of the therapeutic formulation; and

a pressure sensitive adhesive.

32. The method of claim 31 wherein the adhesive patch can effectively cover the entire skin surface that is inflicted with the topical disorder.

33. The method of claim 32 wherein the topical discomfort is itching.

34. The method of claim 33 wherein the itching is caused by an insect bite, a rash, a skin irritation, poison ivy, poison oak, inflammatory skin condition, poison sumac, or any combination thereof.

35. A method for protecting skin inflicted with a topical disorder or for facilitating the healing process of skin inflicted with a topical disorder comprising:

applying to the area of the skin inflicted with the topical disorder an adhesive patch comprising a backing of a flexible sheet of water insoluble porous material, the backing having a front side and a back side and a therapeutic formulation positioned on at least a portion of the front side;

wherein the therapeutic formulation comprises;

camphor present up to about 3.0 wt. % of the therapeutic formulation;

menthol present up to about 1.0 wt. % of the therapeutic formulation; and

a pressure sensitive adhesive.

36. The method of claim 35 wherein the non-occlusive adhesive patch can effectively cover the entire skin surface that is inflicted with the topical disorder.

37. The method of claim 36 wherein the topical discomfort is itching.

38. The method of claim 37 wherein the itching is caused by an insect bite, a rash, a skin irritation, poison ivy, poison oak, an inflammatory skin condition, poison sumac, or any combination thereof.

39. The method of claim 35 wherein the skin patch prevents or diminishes the occurrence of a contaminant from the surrounding environment from contacting the surface of the skin inflicted with the topical disorder.

40. The method of claim 39 wherein the contaminant is clothing, a fingernail, hair, or grass.

41. The method of claim 35 wherein the skin patch prevents or diminishes the occurrence of a patient from scratching, picking, poking, or otherwise touching the topical disorder.

42. A method for alleviating topical discomfort comprising:

applying to the entire skin surface inflicted with the topical disorder an adhesive patch comprising a backing of a flexible sheet of water insoluble porous material, the backing having a front side and a back side and a therapeutic formulation positioned on at least a portion of the front side;

wherein the therapeutic formulation comprises;

camphor present up to about 3.0 wt. % of the therapeutic formulation;

menthol present up to about 1.0 wt. % of the therapeutic formulation; and

a pressure sensitive adhesive.

43. A method for protecting skin inflicted with a topical disorder or for facilitating the healing process of skin inflicted with a topical disorder comprising:

applying to the entire skin surface inflicted with the topical disorder an adhesive patch comprising a backing of a flexible sheet of water insoluble porous material, the backing having a front side and a back side and a therapeutic formulation positioned on at least a portion of the front side;

wherein the therapeutic formulation comprises;

camphor present up to about 3.0 wt. % of the therapeutic formulation;

menthol present up to about 1.0 wt. % of the therapeutic formulation; and

a pressure sensitive adhesive.

44. A method for alleviating topical discomfort comprising:

applying to the area of the skin inflicted with the topical disorder an adhesive patch comprising a backing of a flexible sheet of water insoluble porous material, the backing having a front side and a back side and an ointment positioned on the front side of the backing;

wherein the ointment comprises;

camphor present up to about 3.0 wt. % of the therapeutic formulation;

menthol present up to about 1.0 wt. % of the therapeutic formulation; and

a pressure sensitive adhesive.

45. An adhesive patch comprising a backing of a flexible sheet of water insoluble porous material, the backing having a front side and a back side and a therapeutic formulation positioned on at least a portion of the front side;

wherein the therapeutic formulation comprises;

camphor present up to about 3.0 wt. % of the therapeutic formulation;

menthol present up to about 1.0 wt. % of the therapeutic formulation;

aloe vera;

calamine;

glycerin;

karaya;

polyethylene glycol;

propylene glycol; and

an adhesive.

46. An adhesive patch comprising a backing of a flexible sheet of water insoluble porous material, the backing having a front side and a back side and a therapeutic formulation positioned on at least a portion of the front side;

wherein the therapeutic formulation comprises;

a medicament useful for relieving topical discomfort, wherein the medicament is at least one of camphor, menthol, benzocaine, butamben picrate, dibucaine, dibucaine hydrochloride, dimethisoquin hydrochloride, dyclonine hydrochloride, lidocaine, lidocaine hydrochloride, pramoxine hydrochloride, tetracaine, tetracaine hydrochloride, benzyl alcohol, camphorated metacresol, juniper tar, phenol, phenolate sodium, resorcinol, diphenhydramine hydrochloride, tripelennamine hydrochloride, hydrocortisone, a corticosteroid, and hydrocortisone acetate; and

a pressure sensitive adhesive;

wherein the camphor is present up to about 3.0 wt. % of the therapeutic formulation and menthol is present up to about 1.0 wt. % of the therapeutic formulation;

benzocaine is present in above about 5.0 wt. % to about 20.0 wt. % of the therapeutic formulation;

butamben picrate is present in about 0.5 wt. % to about 1.5 wt. % of the therapeutic formulation;

dibucaine is present in about 0.25 wt. % to about 1.0 wt. % of the therapeutic formulation;

dibucaine hydrochloride is present in about 0.25 wt. % to about 1.0 wt. % of the therapeutic formulation;

dimethisoquin hydrochloride is present in about 0.3 wt. % to about 0.5 wt. % of the therapeutic formulation;

dyclonine hydrochloride is present in about 0.5 wt. % to about 1.0 wt. % of the therapeutic formulation;

lidocaine is present in about 0.5 wt. % to about 4.0 wt. % of the therapeutic formulation;

lidocaine hydrochloride is present in about 0.5 wt. % to about 4.0 wt. % of the therapeutic formulation;

pramoxine hydrochloride is present in about 0.5 wt. % to about 1.0 wt. % of the therapeutic formulation;

tetracaine is present in about 1.0 wt. % to about 2.0 wt. % of the therapeutic formulation;

tetracaine hydrochloride is present in about 1.0 wt. % to about 2.0 wt. % of the therapeutic formulation;

benzyl alcohol is present in about 10.0 wt. % to about 33.0 wt. % of the therapeutic formulation;

camphor is present in about 0.1 wt. % to about 3.0 wt. % of the therapeutic formulation;

juniper tar is present in about 1.0 wt. % to about 5.0 wt. % of the therapeutic formulation;

phenolate sodium is present in about 0.5 wt. % to about 1.5 wt. % of the therapeutic formulation;

resorcinol is present in about 0.5 wt. % to about 3.0 wt. % of the therapeutic formulation;

diphenhydramine hydrochloride is present in about 1.0 wt. % to about 2.0 wt. % of the therapeutic formulation;

tripelennamine hydrochloride is present in about 0.5 wt. % to about 2.0 wt. % of the therapeutic formulation;

hydrocortisone is present in about 0.25 wt. % to less than about 1.0 wt. % of the therapeutic formulation;

corticosteroid is present in about 0.25 to about 5.0 wt. % of the therapeutic formulation;

camphor is present in about 3 wt. % to about 10.8 wt. % of the therapeutic formulation with phenol;

camphor is present in about 3 wt. % to about 10.8 wt. % of the therapeutic formulation with metacresol in about 1 wt. % to about 3.6 wt. % of the therapeutic formulation, as camphorated metacresol;

or hydrocortisone acetate is present in about 0.25 wt. % to about 1.0 wt. % of the therapeutic formulation.